RPG Life Sciences is currently trading at Rs 395.00, up by 42.50 points or 12.06% from its previous closing of Rs 352.50 on the BSE.
The scrip opened at Rs. 378.00 and has touched a high and low of Rs 402.40 and Rs 370.95 respectively. So far 296018 shares were traded on the counter.
The BSE group 'B ' stock of face value Rs 8 has touched a 52 week high of Rs 402.40 on 28-July-2016 and a 52 week low of Rs 138.00 on 24-Aug-2015.
Last one week high and low of the scrip stood at Rs 402.40 and Rs 276.00 respectively. The current market cap of the company is Rs 656.65 crore.
The promoters holding in the company stood at 66.79%, while Institutions and Non-Institutions held 0.31% and 32.90% respectively.
RPG Life Sciences of the RPG Group has signed an agreement to acquire seven prescription brands from Sun Pharmaceuticals Industries for Rs 41 crore. The agreement is in line with company’s strategy to focus on formulations business. The acquired brands are primarily in respiratory and urology segments.
In addition to this, three products will complement the company’s existing range. The deal is subject to approval by the Competition Commission of India (CCI).
RPG Life Sciences is an integrated pharmaceutical company operating in the domestic and international markets in the Branded Formulations, Global Generics, Synthetic and Fermentation APIs space. The company is a research based, pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: